Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2018 / N 2

Эндотелиальная дисфункция и окислительный стресс при церебральном атеросклерозе и возможности их патогенетической коррекции
И.С. Бакулин, М.М. Танашян, А.А. Раскуражев

References

1. Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circulation Research 2017 Feb;120(3):439-48.
2. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. Neurology 2017 Nov;16(11):877-97.
3. Stakhovskaya LV, Klochikhina OA, Bogatyreva MD, Kovalenko VV. Epidemiology of stroke in the Russian Federation: results of territory’s population registry (2009–2010). S.S. Korsakov Journal of Neurology and Psychiatry 2013;113(5):4-10 (In Russian).
4. Kadykov AS, Manvelov LS, Shakhparonova NV. Cronic cerebrovascular diseases (discirculatory encephalopathy). Moscow: Geotar-Media; 2006. 224 p. (In Russian).
5. Chen WH, Jin W, Lyu PY, Liu Y, Li R, Hu M, Xiao XJ. Carotid atherosclerosis and cognitive impairment in nonstroke patients. Chinise Medical Journal (Engl.) 2017 Oct;130(19):2375-9.
6. Barbay M, Taillia H, Nedelec-Ciceri C, Arnoux A, Puy L, Wiener E, Canaple S, Lamy C, Godefroy O, Roussel M; GRECOGVASC Study Group. Vascular cognitive impairment: advances and trends. Revue Neurologique (Paris) 2017 Jul-Aug;173(7-8):473-80.
7. Suslina ZA, Varakin YuYa. Epidemiological aspects of stroke study: time to sum it up. Annals of Clinical and Experimental Neurology 2007;1(2):22-8 (In Russian).
8. Tanashyan MM, Maksyutkina LN, Lagoda OV, Raskurazhev AA, Shabalina AA, Kostyreva M.V. Cerebrovascular diseases and carotid atherosclerosis: biomarkers of inflammation and coagulation. Clinical Neurology 2013;3:16-24 (In Russian).
9. Suslina ZA, Tanashyan MM, Lagoda OV. Atherosclerosis and ischemic disorders of cerebral circulation. Atherothrombosis 2009;2(3):60-7 (In Russian).
10. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nature Immunology 2011 Mar;12(3):204-12.
11. Gutiérrez E, Flammer AJ, Lerman LO, Elízaga J, Lerman A, Fernández-Avilés F. Endothelial dysfunction over the course of coronary artery disease. The European Heart Journal 2013 Nov;34(41):3175-81.
12. Jensen HA, Mehta JL. Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis. Expert Review of Cardiovascular Therapy 2016 Sep;14(9):1021-33.
13. Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circulation Research 2016 Feb;118(4):620-36.
14. Konukoglu D, Uzun H. Endothelial dysfunction and hypertension. Advances in Experimental Medicine and Biology 2017 Jan;956:511-40.
15. Domashenko MA, Orlov SV, Kostyreva MV, Tanashyan MM, Ionova VG, Chechetkin AO, Suslina ZA. Endothelial dysfunction in ischemic disorders of cerebral circulation in the background of coronary heart disease. Russian Heart Journal 2006;7(31):376-8 (In Russian).
16. Tanashyan MM, Suslina ZA, Ionova VG, Domashenko MA, Orlov SV, Chechetkin AO, Pleshkova MYu. Endothelium function state in patients with ischemic insult at different forms of carotid arteries atherosclerotic lesion. VM Bekhterev Neurological Bulletin 2007;39(1):12-6 (In Russian).
17. Dhananjayan R, Koundinya KS, Malati T, Kutala VK. Endothelial dysfunction in type 2 diabetes mellitus. Indian Journal of Clinical Biochemistry 2016 Oct;31(4):372-9.
18. Engin A. Endothelial dysfunction in obesity. In: Obesity and lipotoxicity. Advances in experimental medicine and biology. V. 960. Engin AB, Engin A, editors. Besevler, Ankara, Turkey: Springer; 2017: 345-79.
19. Cerebrovascular diseases and metabolic syndrome. A guide for physicians. Tanashyan MM, editor. Moscow: AST 345; 2017. 334 p. (In Russian).
20. Chen JY, Ye ZX, Wang XF, Chang J, Yang MW, Zhong HH, Hong FF, Yang SL. Nitric oxide bioavailability dysfunction involves in atherosclerosis. Biomedicine & Pharmacotherapy 2018 Jan;97:423-8.
21. Khaddaj Mallat R, Mathew John C, Kendrick DJ, Braun AP. The vascular endothelium: a regulator of arterial tone and interface for the immune system. Critical Reviews in Clinical Laboratory Sciences 2017 Nov-Dec;54(7-8):458-70.
22. Bohlen HG. Nitric oxide and the cardiovascular system. Comprehensive Physiology 2015 Apr;5(2):808-23.
23. Marsh N, Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clinical and Experimental Pharmacology & Physiology 2000 Apr;27(4):313-9.
24. Daff S. NO synthase: structures and mechanisms. Nitric Oxide 2010;23(1):1-11.
25. Li H, Poulos TL. Structure-function studies on nitric oxide synthases. Journal of Inorganic Biochemistry 2005;99(1):293-305.
26. Oliveira-Paula GH, Lacchini R, Tanus-Santos JE. Endothelial nitric oxide synthase: from biochemistry and gene structure to clinical implications of NOS3 polymorphisms. Gene 2016 Jan;575(2 Pt 3):584-99.
27. Mudau M, Genis A, Lochner A, Strijdom H. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovascular Journal of Africa 2012 May;23(4):222-31.
28. da Costa Escobar Piccoli J, Manfredini V, Hamester FI, Bandinelli JB, Turkienicz IM, Chies JA, Peres A, Bodanese LC, Bogo MR. Interaction between endothelial nitric oxide synthase gene polymorphisms (–786T>C, 894G>T and intron 4 a/b) and cardiovascular risk factors in acute coronary syndromes. Archieves of Medical Research 2012 Apr;43(3):205-11.
29. Yao YS, Chang WW, Jin YL, He LP. An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with ischemic stroke. Gene 2013 Oct;528(2):84-92.
30. Imamura A, Takahashi R, Murakami R, Kataoka H, Cheng XW, Numaguchi Y, Murohara T, Okumura K. The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels. European Journal of Endocrinology 2008 Feb; 158(2):189-95.
31. Antoniades C, Tousoulis D, Vasiliadou C, Pitsavos C, Chrysochoou C, Panagiotakos D, Tentolouris C, Marinou K, Koumallos N, Stefanadis C. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. Journal of the American Collage of Cardiology 2005 Sep;46(6):1101-9.
32. Kumar A, Misra S, Kumar P, Prasad K, Pandit AK, Chakravarty K, Kathuria P, Gulati A. Association between endothelial nitric oxide synthase gene polymorphisms and risk of ischemic stroke: a meta-analysis. Neurology India 2017 Jan-Feb;65(1):22-34.
33. Han Y, Xu W, Zhang W, Liu N, Ji Y. T-786C polymorphism in the endothelial nitric oxide synthase gene is associated with increased risk of coronary artery disease in a Chinese population. Pharmacology 2010;85(4):211-6.
34. Lefer DJ, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, Huang PL, Scalia R. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. American Journal of Physiology 1999 Jun;276(6 Pt 2):H1943-50.
35. Tomita H, Egashira K, Kubo-Inoue M, Usui M, Koyanagi M, Shimokawa H, Takeya M, Yoshimura T, Takeshita A. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arteriosclerosis, Thrombosis, and Vascular Biology 1998 Sep;18(9):1456-64.
36. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001 Jul;104(4):448-54.
37. Yang X, Li Y, Li Y, Ren X, Zhang X, Hu D, Gao Y, Xing Y, Shang H. Oxidative stress-mediated atherosclerosis: mechanisms and therapies. Frontiers in Physiology 2017 Aug;8:600.
38. Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascular Pharmacology 2018 Jan;100:1-19.
39. Varghese JF, Patel R, Yadav UCS. Novel insights in the metabolic syndrome-induced oxidative stress and inflammation-mediated atherosclerosis. Current Cardiology Reviews 2018 Mar;14(1):4-14.
40. Searles CD. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression. American Journal of Physiology. Cell Physiology 2006 Nov;291(5):C803-16.
41. Förstermann U. Nitric oxide and oxidative stress in vascular disease. Pflügers Archiv 2010 May;459(6):923-39.
42. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010 Nov;468(7327):1115-8.
43. Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative stress in atherosclerosis. Current Atherosclerosis Reports 2017 Sep;19(11):42.
44. Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J, Dellsperger KC, Zhang C. Role of TNF-α in vascular dysfunction. Clinical Science (London) 2009 Feb;116(3):219-30.
45. Kumar RG, Spurthi MK, Kumar KG, Sahu SK, Rani SH. Endothelial nitric oxide synthase polymorphism G298T in association with oxidative DNA damage in coronary atherosclerosis. Journal of Genetics 2012;91(3):349-52.
46. Alpoim PN, Sousa LP, Mota AP, Rios DR, Dusse LM. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease. Clinica Chimica Acta 2015 Feb;440:36-9.
47. Tanashyan MM, Raskurazhev AA, Shabalina AA, Lagoda OV, Gnedovskaya EV. Biomarkers of cerebral atherosclerosis: the capabilities of early diagnosis and prognosis of individual risk. Annals of Clinical and Experimental Neurology 2015;9(3):20-5 (In Russian).
48. Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators of Inflammation 2013;2013:152786.
49. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circulation Research 2014 Jun;114(12):1852-66.
50. Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells. Arteriosclerosis, Thrombosis and Vascular Biology 2015 Feb;35(2):280-7.
51. Klingenberg R, Gerdes N, Badeau RM, Gisterå A, Strodthoff D, Ketelhuth DF, Lundberg AM, Rudling M, Nilsson SK, Olivecrona G, Zoller S, Lohmann C, Lüscher TF, Jauhiainen M, Sparwasser T, Hansson GK. Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. Journal of Clinical Investigation 2013 Mar;123(3):1323-34.
52. Zhang WC, Wang J, Shu YW, Tang TT, Zhu ZF, Xia N, Nie SF, Liu J, Zhou SF, Li JJ, Xiao H, Yuan J, Liao MY, Cheng LX, Liao YH, Cheng X. Impaired thymic export and increased apoptosis account for regulatory T cell defects in patients with non-ST segment elevation acute coronary syndrome. Journal of Biological Chemistry 2012 Oct;287(41):34157-66.
53. Epstein OI. Release activity: from phenomenon to creation of new medicines. Bulletin of Experimental Biology and Medicine 2012;154(7):62-7 (In Russian).
54. Epstein OI, Stark MB, Dygay AM, Sergeeva SA, Goldberg ED, Petrov VI, Voronina TA, Starostina MV. Pharmacology of ultra-low doses of antibodies to endogenous function regulators. Moscow: Russian Academy of Medical Sciences; 2005. 226 p. (In Russian).
55. Neymark AI, Aliyev RT, Muzalevskaya NI. Kraynichenko SV, Vorobyova EN. Treatment of erectile dysfunction in patients with ischemic heart disease and angina of effort. Urologiia 2007;4:76-81 (In Russian).
56. Sattarov ShZ, Mutalova EG, Nigmatullina AE, Golubkova VN. Correction by impaza of erectile dysfunction in patients with arterial hypertension. Lechashchiy Vrach 2006;7:4-6 (In Russian).
57. Kubista H, Donato R, Hermann A. S100 calcium binding protein affects neuronal electrical discharge activity by modulation of potassium currents. Neuroscience 1999 May;90(2):493-508.
58. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, Tubaro C, Giambanco I. S100B’s double life: intracellular regulator and extracellular signal. Biochimica et Biophysica Acta 2009 Jul;1793(6):1008-22.
59. Astrand R, Undén J, Romner B. Clinical use of the calcium-binding S100B protein. Methods of Molecular Biology 2013;963:373-84.
60. Khakimova GR, Voronina TA, Dugina YuL, Ertuzun IA, Epstein OI. The spectrum of pharmacological effects of antibodies to S100 protein in release-active form and mechanisms of their implementation. SS Korsakov Journal of Neurology and Psychiatry 2016;116(4):100-13. (In Russian).
61. Romanov GA, Voronina TA, Sergeeva SA, Barskov IV, Dugina YuL, Epstein OI. Study of antiischemic, neuroprotective actions of proproten. Siberian Herald of Psychiatry and Addiction Psychiatry 2003;1:123-5 (In Russian).
62. Pankova TM, Starostina MV, Stark MB, Epstein OI. Neuroprotective effect of ultra-low doses of antibodies to S100 protein in neuroblastoma culture during oxygen and glucose deprivation. Bulletin of Experimental Biology and Medicine 2007;144(9):260-3 (In Russian).
63. Voronina TA, Sergeeva SA, Martyushev-Poklad AV, Duguna JL, Epstein OI. Antibodies to S-100 protein in anxiety-depressive disorders in experimental and clinical conditions. In: Animal models in biological psychiatry. Kalueff AV, editor. New York: Nova Science Publishers; 2006: 137-52.
64. Epstein OI, Molodavkin GM, Voronina TA, Sergeeva SA. Antidepressant properties of proproten and amitriptyline: a comparative experimental study. Bulletin of Experimental Biology and Medicine 2003;145(Suppl 1):34-6 (In Russian).
65. Amosov ML, Saleev RA, Zarubina EV, Makarova TV. Tenoten application for the treatment of emotional disorders in patients with transient (cerebral) ischemic attacks (TIAs). Russian Journal of Psychiatry 2008;3:72-5 (In Russian).
66. Sharkov SB, Shirshova EV, Kuzmin VYu. Ultra-low doses of antibodies to S100 protein in the treatment of autonomic disorders and anxiety in patients with organic and functional diseases of the (CNS). Lechashchiy Vrach 2008;8:18-23 (In Russian).
67. Shavlovskaya OA. Tenoten in clinical practice. Effective Pharmacotherapy. Neurology and Psychiatry 2011;4:18-22 (In Russian).
68. Ganinа KK, Duginа YuL, Zhavbert ES, Ertuzun IA, Epstein OI, Mukhin VN, Abdurasulova IN. Anti-amnesic effects of divaza and its components on the model of β-amyloid amnesia in rats. SS Korsakov Journal of Neurology and Psychiatry 2016;9:69-74 (In Russian).
69. Zhavbert ES, Guryanova NN, Surkova EI., Dugina YuL, Kachaeva EV, Epstein OI, Myshkin VA, Gurto RV. Study of divasa influence on lipid peroxidation. In: Proceedings of the XXI Russian national Congress "Man and Medicine". Moscow, 2014 Apr 4–11. Moscow, 2014: 242 (In Russian).
70. Rachyn AP, Vygovskaya SN, Nuvakhova MB, Voropaev AA, Tarasova LYu, Rachyn SA, Smirnova DV. Chronic cerebrovascular pathology, endotelialny dysfunction and the efficacy of release-active drugs to endogenous regulators of brain. Lechashchiy Vrach 2018;3:89-95 (In Russian).
71. Vorobyova OV, Kamchatnov PR, Rachin AP. Efficacy and safety of the novel neurotropic Divaza drug in complex therapy of chronic cerebral ischemia. Effective pharmacotherapy 2014;31:62-8 (In Russian).
72. Kamchatnov PR, Vorobyova OV, Rachin AP. Treatment of emotional and cognitive disorders in patients with chronic cerebral ischemia. SS Korsakov Journal of Neurology and Psychiatry 2014;4:52-7 (In Russian).
73. Chukanova EI, Bogolepova AN, Chukanova AS. Divasa application in cerebrovascular insufficiency treatment. SS Korsakov Journal of Neurology and Psychiatry 2015;115(6):17-23 (In Russian).
74. Fateeva VV, Shumakher GI, Vorobyeva EN, Khoreva MA, Voskanyan LR. The efficacy and safety of divaza drug therapy in patients with chronic cerebral ischemia. SS Korsakov Journal of Neurology and Psychiatry 2017;117(2):32-7 (In Russian).
75. Fateeva VV, Vorobyeva OV, Glazunov A. B. Endothelial dysfunction: a pharmacological target in therapy of affective disorders in patients with cardiovascular diseases. Consilium Medicum 2017;19(2-1):86-9 (In Russian).
76. Parfenov VA, Kamchatnov PR, Vorobyova OV, Gustov AV, Glushkov KS, Doronina OB. Results of multicenter study of efficacy and safety of divaza in treatment of asthenic, mild, and moderate cognitive impairments in elderly and senile patients. SS Korsakov Journal of Neurology and Psychiatry 2017;9:43-50 (In Russian).
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]